Cost-effectiveness analysis of axicabtagene ciloleucel vs. salvage chemotherapy for relapsed or refractory adult diffuse large B-cell lymphoma in China

Li, N; Zheng, B; Cai, HF; Yang, T; Hong, YD; Liu, MB; Hu, JD

Liu, MB (通讯作者)，Fujian Med Univ Union Hosp, Dept Pharm, Fuzhou, Peoples R China.;Liu, MB (通讯作者)，Fujian Med Univ, Sch Pharm, Fuzhou, Peoples R China.;Hu, JD (通讯作者)，Fujian Med Univ Union Hosp, Fujian Inst Hematol, Dept Hematol, Fujian Prov Key Lab Hematol, Fuzhou, Peoples R China.

SUPPORTIVE CARE IN CANCER, 2022; 30 (7): 6113

Abstract

Purpose Axicabtagene ciloleucel (Axi-Cel, 2 x 10(6) CAR-T cells/kg, single intravenous injection) is a chimeric antigen receptor cell immunotherapy th......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索